Trastuzumab Injection

Drug for full-course treatment of HER2+ breast cancer

Trastuzumab can bind to human epidermal growth factor receptor 2(HER2) receptors with high specificity, prevent EGF from rebinding to HER2, and then delay the growth of tumor cells. It is widely used in the treatment for metastatic breast cancer,early-stage breast cancer and metastatic gastric cancer. The brand-name product of trastuzumab was launched in the United States in 1998. With its excellent clinical profiles, trastuzumab with expanded indications has become a drug used in the full treatment course of HER2+breast cancer with great significance in this field.

Indications:

HER2-positive metastatic breast cancer. 

HER2-positive early breast cancer. 

Adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction.

STRENGTH:

150mg/vial